MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment

Not Applicable
Conditions
Congenital Myopathy
Myosin Storage Myopathy
Neuromuscular Diseases
Musculoskeletal Diseases
Nemaline Myopathy
Centronuclear Myopathy
Interventions
First Posted Date
2021-10-29
Last Posted Date
2023-05-30
Lead Sponsor
Vastra Gotaland Region
Target Recruit Count
20
Registration Number
NCT05099107
Locations
🇸🇪

Sahlgrenska university hospital, Gothenburg, Västra Götaland, Sweden

Salbutamol Use in Ozone Air Pollution by People With Asthma and/or Exercise Induced Bronchoconstriction (EIB)

Phase 4
Completed
Conditions
Asthma and/or Exercise Induced Bronchoconstriction
Ozone Air Pollution
Interventions
Drug: Placebo medication
Other: Ozone
Other: Filtered Air
Other: Exercise
First Posted Date
2021-10-21
Last Posted Date
2025-03-14
Lead Sponsor
University of British Columbia
Target Recruit Count
18
Registration Number
NCT05087693
Locations
🇨🇦

Environmental Physiology Laboratory, Vancouver, British Columbia, Canada

Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma

Phase 1
Recruiting
Conditions
Asthma
Interventions
Drug: Interferon gamma-primed mesenchymal stromal cells (MSCs)
First Posted Date
2021-09-05
Last Posted Date
2023-08-24
Lead Sponsor
Emory University
Target Recruit Count
12
Registration Number
NCT05035862
Locations
🇺🇸

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

Inhaled Beta-2 Agonist Versus Epinephrine For Treatment of Transient Tachypnea of Newborn (TTN)

Phase 1
Completed
Conditions
Transient Tachypnea of the Newborn
Interventions
First Posted Date
2021-08-16
Last Posted Date
2021-08-16
Lead Sponsor
Ahmed Noaman
Target Recruit Count
135
Registration Number
NCT05006235

Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus

Phase 1
Completed
Conditions
Status Asthmaticus
Interventions
Drug: Magnesium Sulfate 500 mg/ml+ ventolin
First Posted Date
2021-06-18
Last Posted Date
2023-04-05
Lead Sponsor
Ziauddin University
Target Recruit Count
126
Registration Number
NCT04929626
Locations
🇵🇰

Rabia Asif, Karachi, Sindh, Pakistan

Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients with Stable Mild Asthma

Not Applicable
Recruiting
Conditions
Mild Asthma
Interventions
Other: Albuterol Sulfate inhalation Placebo
Other: Methacholine
First Posted Date
2021-06-03
Last Posted Date
2025-02-17
Lead Sponsor
Intech Biopharm Ltd.
Target Recruit Count
148
Registration Number
NCT04912596
Locations
🇮🇳

Dr. Jivraj Mehta Smarak Health Foundation, Ahmedabad, India

🇮🇳

KLEs Dr Prabhakar Kore Hospital & MRC, Belagave, India

🇮🇳

NRS Medical College and Hospital, Kolkata, India

and more 9 locations

Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

Early Phase 1
Recruiting
Conditions
Primary Ciliary Dyskinesia
Interventions
Diagnostic Test: Technetium99m - Sulfur Colloid (Tc99m-SC)
First Posted Date
2021-05-25
Last Posted Date
2024-08-26
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
30
Registration Number
NCT04901715
Locations
🇺🇸

University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States

ProAir Digihaler in COPD Disease Management: A Real World Study

Completed
Conditions
COPD
COPD Exacerbation Acute
First Posted Date
2021-03-30
Last Posted Date
2022-06-24
Lead Sponsor
Pulmonary Research Institute of Southeast Michigan
Target Recruit Count
27
Registration Number
NCT04821869
Locations
🇺🇸

Pulmonary Research Institute of Southeast Michigan, Farmington Hills, Michigan, United States

Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions

First Posted Date
2021-03-18
Last Posted Date
2024-03-18
Lead Sponsor
Intech Biopharm Ltd.
Target Recruit Count
60
Registration Number
NCT04803734
Locations
🇨🇳

Tamshui Mackay Memorial Hospital, New Taipei City, Taiwan

Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents

Phase 4
Completed
Conditions
Asthma in Children
Interventions
First Posted Date
2021-02-11
Last Posted Date
2021-02-11
Lead Sponsor
Rambam Health Care Campus
Target Recruit Count
92
Registration Number
NCT04750603
Locations
🇮🇱

Rambam Medical Center, Haifa, Israel

© Copyright 2025. All Rights Reserved by MedPath